Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease
Authors:
Open Access
- 21 May 2021
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 21 (1) , 1-11
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is an important risk factor for postoperative complications and mortality. To determine the effects of perioperative combination therapy, using a long-acting muscarinic antagonist (LAMA) and a long-acting β2 agonist (LABA), on preoperative lung function, postoperative morbidity and mortality, and long-term outcome in COPD patients. Methods: Between January 2005 and October 2019, 130 consecutive patients with newly diagnosed COPD underwent surgery for lung cancer. We conducted a retrospective review of their medical record to evaluate that LAMA/LABA might be an optimal regimen for patients with COPD undergoing surgery for lung cancer. All patients were received perioperative rehabilitation and divided into 3 groups according to the type of perioperative inhaled therapy and management: LAMA/LABA (n = 64), LAMA (n = 23) and rehabilitation only (no bronchodilator) (n = 43). We conducted a retrospective review of their medical records. Results: Patients who received preoperative LAMA/LABA therapy showed significant improvement in lung function before surgery (p < 0.001 for both forced expiratory volume in 1 s (FEV1) and percentage of predicted forced expiratory volume in 1 s (FEV1%pred). Compared with patients who received preoperative LAMA therapy, patients with LAMA/LABA therapy had significantly improved lung function (ΔFEV1, LAMA/LABA 223.1 mL vs. LAMA 130.0 mL, ΔFEV1%pred, LAMA/LABA 10.8% vs. LAMA 6.8%; both p < 0.05). Postoperative complications were lower frequent in the LAMA/LABA group than in the LAMA group (p = 0.007). In patients with moderate to severe air flow limitation (n = 61), those who received LAMA/LABA therapy had significantly longer overall survival and disease-free survival compared with the LAMA (p = 0.049, p = 0.026) and rehabilitation-only groups (p = 0.001, p < 0.001). Perioperative LAMA/LABA therapy was also associated with lower recurrence rates (vs. LAMA p = 0.006, vs. rehabilitation-only p = 0.008). Conclusions: We believe this treatment combination is optimal for patients with lung cancer and COPD.Keywords
All Related Versions
This publication has 24 references indexed in Scilit:
- Prevalence of and risk factors for postoperative pulmonary complications after lung cancer surgery in patients with early-stage COPDInternational Journal of Chronic Obstructive Pulmonary Disease, 2016
- Global burden of COPDRespirology, 2015
- Impact of COPD on Postoperative OutcomesChest, 2013
- Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPDPulmonary Pharmacology & Therapeutics, 2010
- Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPDRespirology, 2009
- COPD prevalence is increased in lung cancer, independent of age, sex and smoking historyEuropean Respiratory Journal, 2009
- Association of Chronic Obstructive Pulmonary Disease and Tumor Recurrence in Patients With Stage IA Lung Cancer After Complete ResectionThe Annals of Thoracic Surgery, 2007
- Familial Lung CancerAmerican Journal of Respiratory and Critical Care Medicine, 2006
- The role of oxidative stress in mechanisms of metal-induced carcinogenesisCritical Reviews in Oncology/Hematology, 2002
- Deposition and clearance of 2 μ particles in the tracheobronchial tree of normal subjects—smokers and nonsmokersJournal of Clinical Investigation, 1971